Ketamine May Ease Suicidal Thinking in Dual Diagnosis Care

Ketamine can ease suicidal thinking within hours, far faster than conventional antidepressants, and researchers still can’t fully explain the mechanism. A new randomized trial adds a piece to that puzzle. Ketamine’s speed makes the drug relevant to dual diagnosis treatment, especially as suicide rates in certain states continue to grow.

The Trial’s Goals

Researchers from the New York State Psychiatric Institute and Columbia University enrolled 80 adults between 18 and 65, all in an episode of major depressive disorder and scoring 4 or higher on a clinical measure of suicidal ideation. Participants voluntarily enrolled in an inpatient research unit in New York.

Each received a single 40-minute intravenous infusion of either ketamine at 0.5 milligrams per kilogram at well below anesthetic levels or midazolam at 0.02 milligrams per kilogram. Midazolam served as the control because its short-term sedative effects keep participants unaware of which drug they received.

Saliva was collected at waking and 30 minutes later, before treatment and again 24 hours afterward. The final analysis covered 63 participants, 31 on ketamine and 32 on midazolam, after exclusions for sampling problems and dropouts. Researchers controlled for sampling time, tobacco use, caffeine and stable psychiatric medications.

Findings & More

Waking cortisol rose in the ketamine group 24 hours after infusion. The midazolam group showed no meaningful change. The increase persisted past the point where ketamine’s short-lived dissociative effects would have worn off.

Participants with larger cortisol increases tended to report larger reductions in suicidal thinking. That association fell just short of conventional statistical significance, so it’s a signal for further study rather than a finding. The cortisol change wasn’t related to overall depression severity.

The researchers suggested a temporary, moderate rise in morning cortisol might help reset the body’s stress-response system. Whether that drives ketamine’s rapid effect or simply accompanies it remains unresolved.

Speed Matters in Addiction Recovery

Suicide risk is substantially elevated among people with substance use disorders compared with the general population, and it does not distribute evenly across recovery. It concentrates in the hardest stretches: the days after detox, the weeks after a return to use, the period after leaving a residential program.

Those are precisely the windows where a treatment that takes four to six weeks to work is out of step with the risk. A person in early recovery with severe depression and active suicidal thinking needs something that moves on the same timescale as the danger. That’s the clinical argument for fast-acting options and is why mechanism research matters rather than being academic.

Mental Health and Addiction Connection

Ketamine sits awkwardly here. It treats severe depression and is also a substance with real misuse potential. That makes ketamine a live question for anyone with a co-occurring substance use disorder rather than an automatic no.

The answer isn’t to rule it out. It’s to insist that whoever prescribes it knows the full substance use history, that administration is supervised, and that the prescriber coordinates with the rest of the treatment team rather than working in isolation.

Co-occurring disorders means a mental health condition and a substance use disorder present at the same time, which is common. Integrated dual diagnosis treatment addresses both through one coordinated team instead of treating one and referring out for the other.

Treating them in sequence tends to fail because they feed each other. Depression left untreated during addiction care raises relapse risk, and continued substance use blunts psychiatric treatment. When suicidal thinking is in the picture, splitting the two is inefficient and leaves the most dangerous symptom sitting between two providers.

Questions to Ask a Treatment Program

If you’re considering ketamine, ask who supervises administration and what monitoring happens during and after. 

• Does the program treat co-occurring substance use with the same team in the same building? 

• What psychotherapy runs alongside medication, whether group behavioral or trauma-focused therapy?

• What’s Plan B and who watches risk in the meantime?

Comprehensive Treatment with or without Ketamine

Our online and browsable directory lists mental and behavioral treatment centers and dual diagnosis programs by location, level of care, and insurance accepted. You can filter for programs that treat depression and addiction together rather than separately.

Feel free to also dial 800-908-4823 (Sponsored) to speak with an expert on our helpline and explore treatment options.

If you or someone you know struggles with suicidal thoughts, help is available right now. Call or text 988 to reach the Suicide and Crisis Lifeline, any time of day.

Author

Quentin Blount

Content Manager

Read Bio

Quentin brings nearly a decade of experience as a writer, editor, and digital publisher to his role as Content Manager for Rehab.com. He aims to help people better understand their treatment options by creating engaging and informative content that is user-friendly, factually accurate, and optimized for search engine visibility. In his free time, Quentin enjoys the company of his friends, family, and his dog, Coop.

Editor

Peter Lee, PhD

Read Bio

Peter W.Y. Lee is a writer and historian of American history during the Cold War. His primary focus is the relationship between youth and popular culture and its impact on U.S. society during the twentieth century. He has published widely on how the public has used popular culture as a mechanism to address political and social shifts throughout time